Published in Structure on January 01, 2004
Binding isotope effects: boon and bane. Curr Opin Chem Biol (2007) 1.24
Transition States, analogues, and drug development. ACS Chem Biol (2013) 1.15
Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design. Biochem J (2006) 0.83
Structures of native human thymidine phosphorylase and in complex with 5-iodouracil. Biochem Biophys Res Commun (2009) 0.78
Purification, crystallization and preliminary X-ray diffraction study on pyrimidine nucleoside phosphorylase TTHA1771 from Thermus thermophilus HB8. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.75
Indispensable residue for uridine binding in the uridine-cytidine kinase family. Biochem Biophys Rep (2017) 0.75
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res (2005) 4.21
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res (2013) 3.01
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Embryonic assembly of a central pattern generator without sensory input. Nature (2002) 2.38
Autonomous circuitry for substrate exploration in freely moving Drosophila larvae. Curr Biol (2012) 1.99
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest (2015) 1.68
The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. Biochem J (2003) 1.58
The OtsAB pathway is essential for trehalose biosynthesis in Mycobacterium tuberculosis. J Biol Chem (2005) 1.47
Structure and interactions of NCAM Ig1-2-3 suggest a novel zipper mechanism for homophilic adhesion. Structure (2003) 1.45
Embryonic origin of olfactory circuitry in Drosophila: contact and activity-mediated interactions pattern connectivity in the antennal lobe. PLoS Biol (2012) 1.41
Cation-pi interactions as determinants for binding of the compatible solutes glycine betaine and proline betaine by the periplasmic ligand-binding protein ProX from Escherichia coli. J Biol Chem (2003) 1.35
The Mycobacterium tuberculosis ino1 gene is essential for growth and virulence. Mol Microbiol (2004) 1.34
Refining GAL4-driven transgene expression in Drosophila with a GAL80 enhancer-trap. Genesis (2004) 1.34
Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells. J Biol Chem (2001) 1.31
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol (2002) 1.27
Genetic specification of axonal arbors: atonal regulates robo3 to position terminal branches in the Drosophila nervous system. Neuron (2003) 1.24
Embryonic origins of a motor system: motor dendrites form a myotopic map in Drosophila. PLoS Biol (2003) 1.23
The development of motor coordination in Drosophila embryos. Development (2008) 1.22
Structural homeostasis: compensatory adjustments of dendritic arbor geometry in response to variations of synaptic input. PLoS Biol (2008) 1.20
Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol (2007) 1.18
Positional cues in the Drosophila nerve cord: semaphorins pattern the dorso-ventral axis. PLoS Biol (2009) 1.18
Founder myoblasts and fibre number during adult myogenesis in Drosophila. Development (2004) 1.16
myoblasts incompetent encodes a zinc finger transcription factor required to specify fusion-competent myoblasts in Drosophila. Development (2002) 1.16
Endogenous patterns of activity are required for the maturation of a motor network. J Neurosci (2011) 1.15
Hox genes and the regulation of movement in Drosophila. Dev Neurobiol (2008) 1.15
Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol (2002) 1.13
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J Med Chem (2012) 1.12
Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. Biochemistry (2005) 1.11
How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J Biol Chem (2006) 1.07
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther (2007) 1.06
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Bioorg Med Chem Lett (2003) 1.05
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett (2005) 1.04
Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol (2009) 1.02
The X-ray crystal structure and putative ligand-derived peptide binding properties of gamma-aminobutyric acid receptor type A receptor-associated protein. J Biol Chem (2001) 1.02
Crystal structure of inositol 1-phosphate synthase from Mycobacterium tuberculosis, a key enzyme in phosphatidylinositol synthesis. Structure (2002) 1.01
Molecular determinants for substrate specificity of the ligand-binding protein OpuAC from Bacillus subtilis for the compatible solutes glycine betaine and proline betaine. J Mol Biol (2006) 1.00
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther (2011) 1.00
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer (2011) 0.95
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib. PLoS One (2013) 0.95
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther (2012) 0.95
Gateway cloning vectors for the LexA-based binary expression system in Drosophila. Fly (Austin) (2010) 0.94
VEGFR1 (Flt1) regulates Rab4 recycling to control fibronectin polymerization and endothelial vessel branching. Traffic (2009) 0.94
Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett (2005) 0.92
Model-based drug discovery: implementation and impact. Drug Discov Today (2013) 0.91
Regulation of synaptic connectivity: levels of Fasciclin II influence synaptic growth in the Drosophila CNS. J Neurosci (2002) 0.91
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J Med Chem (2012) 0.91
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Bioorg Med Chem Lett (2003) 0.91
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther (2013) 0.91
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 0.90
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem (2002) 0.90
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines. Bioorg Med Chem Lett (2003) 0.89
Crystal structure of the core domain of RhoE/Rnd3: a constitutively activated small G protein. Biochemistry (2002) 0.88
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding. Mol Cancer Ther (2011) 0.88
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem (2012) 0.88
Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis (2010) 0.86
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem (2013) 0.86
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett (2004) 0.85
Crystal structure analysis of the exocytosis-sensitive phosphoprotein, pp63/parafusin (phosphoglucomutase), from Paramecium reveals significant conformational variability. J Mol Biol (2002) 0.85
Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope. J Mol Biol (2010) 0.83
Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett (2004) 0.83
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett (2008) 0.82
The IgLON protein Lachesin is required for the blood-brain barrier in Drosophila. Mol Cell Neurosci (2006) 0.82
Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases. Bioorg Med Chem Lett (2012) 0.82
Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes. MAbs (2014) 0.82
Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo. Bioorg Med Chem Lett (2009) 0.81
Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. J Med Chem (2015) 0.81
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int J Oncol (2011) 0.81
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2. Bioorg Med Chem Lett (2012) 0.81
Solid-phase synthesis and biological evaluation of a pepticinnamin E library. Angew Chem Int Ed Engl (2002) 0.81
Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies. Angiogenesis (2012) 0.80
Initiation of primary myogenesis in amniote limb muscles. Dev Dyn (2013) 0.79
Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide series. Bioorg Med Chem Lett (2012) 0.79
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett (2008) 0.79
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1. Bioorg Med Chem Lett (2012) 0.79
Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors. Bioorg Med Chem Lett (2012) 0.79
Structure guided lead generation for M. tuberculosis thymidylate kinase (Mtb TMK): discovery of 3-cyanopyridone and 1,6-naphthyridin-2-one as potent inhibitors. J Med Chem (2014) 0.78
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J Med Chem (2005) 0.78
Synthesis of cytidine ribonucleotides by stepwise assembly of the heterocycle on a sugar phosphate. Chembiochem (2003) 0.78
Characterization of voltage-gated ionic currents in a peripheral sensory neuron in larval Drosophila. BMC Res Notes (2010) 0.78
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. J Med Chem (2013) 0.78